S&CO Inc. Trims Stock Holdings in Edwards Lifesciences Corporation $EW

S&CO Inc. decreased its position in Edwards Lifesciences Corporation (NYSE:EW) by 0.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 82,147 shares of the medical research company’s stock after selling 650 shares during the quarter. S&CO Inc.’s holdings in Edwards Lifesciences were worth $6,424,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of EW. Brighton Jones LLC purchased a new position in Edwards Lifesciences during the 4th quarter valued at about $266,000. Allworth Financial LP increased its stake in shares of Edwards Lifesciences by 6.3% during the first quarter. Allworth Financial LP now owns 3,513 shares of the medical research company’s stock valued at $264,000 after purchasing an additional 208 shares in the last quarter. Alps Advisors Inc. purchased a new position in shares of Edwards Lifesciences during the first quarter valued at approximately $369,000. Cerity Partners LLC boosted its position in shares of Edwards Lifesciences by 67.9% in the 1st quarter. Cerity Partners LLC now owns 212,923 shares of the medical research company’s stock worth $15,433,000 after purchasing an additional 86,089 shares in the last quarter. Finally, Arizona State Retirement System grew its stake in shares of Edwards Lifesciences by 0.8% in the 1st quarter. Arizona State Retirement System now owns 173,090 shares of the medical research company’s stock worth $12,546,000 after buying an additional 1,363 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on EW shares. Wall Street Zen cut Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. Morgan Stanley raised their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the company an “equal weight” rating in a report on Tuesday, July 15th. Oppenheimer lowered Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 8th. Piper Sandler reiterated an “overweight” rating and issued a $95.00 price target (up previously from $90.00) on shares of Edwards Lifesciences in a research note on Friday, October 31st. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Wednesday, October 8th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $91.39.

Edwards Lifesciences Price Performance

NYSE EW opened at $83.37 on Monday. Edwards Lifesciences Corporation has a one year low of $64.89 and a one year high of $87.09. The stock has a 50-day moving average of $77.78 and a 200 day moving average of $77.41. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The company has a market capitalization of $48.38 billion, a price-to-earnings ratio of 12.00, a PEG ratio of 3.97 and a beta of 1.03.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter last year, the firm posted $0.67 EPS. The business’s quarterly revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. On average, sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. The trade was a 4.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.